Today, Ocumetics has entered the history books. Nearly two decades of relentless innovation, bold ambition, and unwavering belief have led to this defining moment: the first-in-human implantation of the Ocumetics Lens.

What many once thought impossible is now reality. This achievement is not the work of one person or one idea, but the result of years of persistence by an extraordinary team of scientists, engineers, clinical advisors, and partners who refused to let go of a vision to transform human sight.

This is more than a milestone; it is a turning point for ophthalmology and for millions of people worldwide who are waiting for new solutions. And while we celebrate this historic success, we know our mission is far from complete. With more determination than ever, we move forward to deliver the Ocumetics Lens to patients everywhere and reshape the future of vision.

Best regards 

Dean Burns
President, CEO and Director 
Ocumetics Technology

  • Ocumetics Announces Initiation of Patient Recruitment for Upcoming Group Two Human Clinical Surgeries

    Key Highlights Group Two clinical study underway – Patient recruitment has begun in Mexico City, with surgeries targeted for Fall 2026. Moving beyond safety – The Group Two study will evaluate the Ocumetics Lens for safety plus near-and distance-vision performance. Next-generation technology – Patients will receive the latest-generation Ocumetics Lens implanted with an enhanced delivery system. 12-month data milestone approaching – Group One patients are

  • Ocumetics Announces Completion of Third and Final Tranche of Unit Private Placement

    Calgary, Alberta – TheNewswire – August 24, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the third and final tranche of the private placement previously announced by the Corporation on July 7, July 29, July 30, 2026 and July 31, 2026 (the “Offering”).   The Corporation

  • Ocumetics Accelerates Toward Group Two First-In-Human Study with Manufacturing Launch of Optimized Accommodating Lens

    Key Highlights Precision molds received for manufacturing of new optimized accommodating intraocular lenses Production and testing of next-generation lenses now underway New lens design incorporates insights from Group One First-in-Human study Group Two preclinical surgeries targeted for early Q3 2026 FDA Investigational Device Exemption (IDE) preparation advancing Calgary, Canada – TheNewswire – May 12, 2026

  • Ocumetics Announces Offering of Units

    Calgary, Alberta – TheNewswire – April 29, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to